# **GPAT QUESTION PAPER 2004 WITH ANSWER KEY**

## PHARMACEUTICAL SCIENCE

Time: 3 hours Maximum Marks: 150

## Read the following instruction carefully.

- 1. This question paper contains 90 objective questions. Q. 1-30 carry 1 mark each and Q. 31-90 carry two marks each.
- 2. Answer all the questions.
- 3. Questions must be answered on special machine gradable Objective Response Sheet (ORS) by darken-ing the appropriate bubble (marked A, B, C, D) using HB pencil against the question number on the left hand side of the ORS. Each question has only one correct answer. In case you wish to change an answer, erase the old answer completely using a good soft eraser.
- 4. There will be NEGATIVE marking. For each wrong answer, 0.25 mark for Q. 1-30 and 0.5 mark for Q. 31-90 will be deducted. More than one answer marked against a question will be deemed as an incorrect response and will be negative marked.
- 5. Write your registration number, name and name of the Centre at the specified locations on the right half of the ORS.
- 6. Using HB pencil, darken the appropriate bubble under each digit of your registration number.
- 7. Using HB pencil, darken the appropriate bubble under the letters corresponding to your paper code.
- 8. No charts or tables are provided in the examination hall.
- 9. Use the blank pages given at the end of the question paper for rough work.
- 10. Choose the closest numerical answer among the choices given.
- 11. This question paper contains 20 pages. Please report, if there is any discrepancy.

## (Q. 1 - 30) CARRY ONE MARK EACH

- 1. The structural feature common for propranolol, atenolol, pindolol, metoprololin the side chain is
  - (a) Isopropyl amino propan-2-ol

(b) Dimethyl amino propan-2-ol

(c) Diethyl amino propan-2-ol

- (d) Dibutylamino propan-2-ol
- 2. When N- methyl group of morphine is replaced with an allyl group, the compoundformed is
  - (a) Naloxone-morphine antagonist

(b) Naltrexone-morphine antagonist

(c) Nalorphine-morphine antagonist

(d) Nalbuphine-morphine agonist/antagonist

- 3. Nitrazepam can be synthesized from
  - (a) 2-Bromo-5-amino benzophenone
- (b) 2-Nitro-2-chloro acetophenone
- (c) 2-Amino-5-nitro cyclohexanone
- (d) 2-Amino-5 nitro-benzophenone
- 4. Clavulanic acid has a beta lactam ring fused to
  - (a) Thienyl system

(b) Thiodiazole system

(c) Thiazolidine system

(d) Oxazolidine system

5.	A drug which has antipyretic, anti-inflammatory and antiplatelet activity is						
	(a) Sulfinpyrazone		(b)	Aspirin			
	(c) Ticlopidine		(d)	Acetaminophen			
6.	Wild cherry bark contains p	prunasin which is a					
	(a) Phenolic glycoside		(b)	Isothiocyanate glycos	side		
	(c) Coumarin glycoside		(d)	Cyanogenic glycoside			
7.	Ephedra sinica and Ephedro	a equisetina can be disting	guish	ned by type of			
	(a) Branching		(b)	Stomata			
	(c) Scaly leaves.		(d)	Alkaloids			
8.	Microprapagation of the pl	lants is carried out throug	gh				
	(a) Cross fertilization		(b)	Seed germination			
	(c) Plant tissue culture		(d)	Grafting			
9.	Aconitine belongs to the gr	roup of					
	(a) Steroidal alkaloids		(b)	Terpenoidal alkaloid			
	(c) Indole alkaloid		(d)	Quinoline alkaloid			
10.	Crude fibre value of a drug	is measure of					
	(a) Soft tissue matter		(b)	Woody matter			
	(c) Mineral matter		(d)	Organic matter			
11.	One of the units used for e	xpressing pressure is 'tor	r' an	nd is equal to			
	(a) cm of Hg	(b) mm of mercury	(c)	psi	(d)	gause	
12.	Removal of a single electron	n from a molecule results i	in th	e formation of			
	(a) Fragment ion		(b)	Metastable ion			
	(c) Molecular ion		(d)	Rearrangement ion			
13.	Nuclear magnetic movemen	nt is NOT shown by					
	(a) <sup>13</sup> C	(b) <sup>16</sup> O	(c)	<sup>1</sup> H	(d)	<sup>15</sup> N	
14.	Derivatisation techniques i	in HPLC are intended to e	nhan	ice			
	(a) Molecular weight	(b) Detectability	(c)	Reversibility	(d)	Reproducibility	
15.	A conductance cell is calibr	ated by using a solution o	of kn	own conductivity i. e.u	suall	y a solution of	
		(b) $Hg_2Cl_2$			Na <sub>2</sub>	-	
16.	Metoclopramide is genera		,	( )	2	4	
	(a) Prophylaxis of vomitin		(b)	Preventing motion si	ckne	SS	
	(c) Treating irritable bowe	-		Treatment of pancrea			
17.	DNA amplification by the p	oolymerase chain reaction	use	S		-	
	(a) Thermus aquatiucs DN	A polymerase	(b)	DNA topoisomerase			
	(c) RNA polymerase		(d)	RNA helicase			
18.	Identify the non-pathogenic	c organism					
	(a) Mycobacterium bovis	~	(b)	Mycobacterium smegn	natis		
	(c) Mycobacterium avium		. ,	Mycobacterium intrac			
				-			

19.	Bioassay are carried out to		
	(a) Measure the pharmacological activity of a drug		
	(b) Avoid clinical trials for newdrugs		
	(c) Detect the impurity in a given drug		
	(d) Screen for pharmacogeniticInfluences of new d	rugs	
20.	A direct way of studying idiosyncratic reactions to the	he gi	ven drug is by
	(a) Changing the route of drug administration		
	(b) Change the assay method		
	(c) Pharmacogenomic		
	(d) Structure activity relationship studies of a family	of c	ompounds
21.	An example of haemopoietic growth factor is		
	(a) Platelet derived factor	(b)	Epidermal growth factor
	(c) Iron dextran	(d)	Erythropoietin
22.	Safranin is used as a reagent to detect		
	(a) Gram-negative bacteria	(b)	Gram-positive bacteria
	(c) Acid fast bacteria	(d)	Myxozoa
23.	Sulphonamides do not have adverse drug interaction	wit	1
	(a) Oral anticoagulants		
	(b) Sulfonylurea hypoglycemic agent		
	(c) Hydantoin anticonvulsant		
	(d) Dihydro folate reductase inhibitors		
24.	Simvastatin belongs to		
	(a) HMG CoA reductase inhibitor type of antilipiden	nic a	gents
	(b) HMG CoAreductase inhibitor type of anticoagula	ant a	gents
	(c) Fibrate type of anticoagulantagents		
	(d) Fibrate type of antilipidemic agents		
25.	HIV infection can be clinically controlled with		
	(a) Cytarabine (b) Acyclovir	(c)	Zidovudine (d) Amantadine
26.	The measure of cohesive strength of the cross lin	nking	g that occurs between gelatin molecules and is
	proportional to the molecular weight of gelatin is so	calle	d
	(a) Bloom Strength	(b)	Viscosity
	(c) Surface tension	(d)	Partition coefficient
27.	A water soluble substance used as coating material	in m	croencapsulation process is
	(a) Polyethylene	(b)	Silicone
	(c) Hydroxy ethyl cellulose	(d)	Paraffin
28.	One of the following is used as a solubilizing agen	t to	solubilize testosterone inpharmaceutical liquid
	dosage forms.		
	(a) Sucrose monoesters		Lanolin esters
	(c) Lanoline ethers	(d)	Tween

29.	One of the following is used as a pH dependent cont		•		
	(a) Carnauba wax	, ,	Hydroxyl propyl met	•	cellulose phthalate
	(c) Methyl cellulose		Glyceryl monosterate		
30.					
	(a) Schedule B (b) Schedule F	(c)	Schedule O	(d)	Schedule M
	(Q.31-90) CARRY T	wo	MARK EACH		
31.	The carboxyl group of aspirin is esterified with N-a	cetyl	-p-aminophenol to get		
	(a) 3-Acetamidophenyl-o-acetyl salicylate	(b)	4-Acetamidophenyl-o	-acet	tyl salicylate
	(c) O-(2-hydroxy benzoyl) salicylic acid	(d)	2-Acetamidophenyl-o	-acet	tyl salicytate
32.	IUPAC system of nomenclature for Diclophenac so	dium	<b>1(BP)</b> is		
	(a) Sodium 2-[(2,6-Dichlorophenyl) amino] phenyl	l acet	tate		
	(b) Sodium 3-[(2,6-Dichlorophenyl)amino] phenyl	acet	ate		
	(c) Sodium 2-[(2-Chlorophenyl) amino] phenyl acc	etate			
	(d) Sodium 2-[(6-Chlorophenyl) amino] phenyl acc	etate			
33.	1-(2-Aminoethyl) perhydroazocine on treatment w	ith S	-methyl isothiourea g	ives	rise to an adrenergic
	neuron blocking agent				
	(a) Bethanidine	(b)	Mecamylamine		
	(c) Guanadrel	(d)	Guanethidine		
34.	Quercetin is				
	(a) 5, 7, 3'-Trihydroxy flavones	(b)	5, 7, 3', 4'-Trihydroxy	flavo	ones
	(c) 3, 5, 7, 3', 4'-Pentahydroxy flavonol	(d)	3, 5, 7, 3', 4'-Pentahye	droxy	y dlavonone
35.	Meconic acid is a chemical market for the genus				
	(a) Piper (b) Pilocarpus	(c)	Prunus	(d)	Papaver
36.	A novel diterpenoid isolated from the of Taxus brevi	folia	is		
	(a) Demecokine (b) Paclitaxel	(c)	Vinblastin	(d)	Brevifolicin
37.	The absorption maximum for polar compound is usu	ally s	shifted with change in	polar	rity of the solvents due
	to				
	(a) Hydrogen bonding	(b)	Chemical reaction		
	(c) Ionization of the compound	(d)	Change in the chrom	opho	ore
38.	A titration in which potential applied across two elec	trode	is maintained at a cons	stant	value and the current
	is measured and plotted against volume of titrant is				
	(a) Potentiometric titration	(b)	Amperometric titration	on	
	(c) Displacement titration	(d)	Conductometric titrat	ion	
39.	The parameter in the elution curve that is propor	tion	al to the concenterati	on o	f a compound in gas
	chromatographic effluent is the				
	(a) Number of peaks	(b)	Width of the peak		
	(c) Area under the peak	(d)	Shape of the peak		

40.	A drug solution has a ha	if fife of 21 days. Assum	ing that i	tne arug unaergo	oes first or	aer kinetics, now iong		
	will it take for the poten	cy to drop to 90% of the	e initial p	otency				
	(a) 3.2 days	(b) 9.6 days	(c)	16 days	(d)	6.4 days		
41.	An amphoteric surfactar	it used in pharmaceutic	al disper	se systems is				
	(a) Bile salts		(b)	Lecithin				
	(c) Sorbitan monolaura	te	(d)	Sorbitan mono	stearate			
42.	An abrasive used in den	tifrices is						
	(a) Dicakium phosphat	e	(b)	Sodium carbox	y methyl c	ellulose		
	(c) Sodium lauryl sulfat	e	(d)	Dioctyl sodium	sulfosucci	nate		
43.	An electrochemical meth	od that enhances the tr	ansport (	of some solute n	nolecules by	creating a potentia		
	gradient through skin tis	ssue with an applied ele	ctrical cu	rrent or voltage	is called			
	(a) Electrophoresis	(b) Iontophoresis	(c)	Osmosis	(d)	Implants		
44.	Apatient with rheumato	id arthritis has been tal	king acet	yl salicylic acid	regularly. H	lowever, recently she		
	has been experiencing stiffness, swelling andpain due to salicylate resistance. She has occult blood in her							
	feaeces. Suggest an appr	opriate drug suitable fo	r her fro	m those mention	ned below			
	(a) Paracetamol	(b) Celecoxib	(c)	Piroxicam	(d)	Naproxen		
45.	The break down of fibrir	ı is catalysed by						
	(a) Plasmin	(b) Renin	(c)	Urokinase	(d)	Ptylin		
46.	Which one of these bes	t describes a process o	carried o	ut to render a c	lrug pharn	nacokinetically more		
	acceptable http://www.x	.amstudy.com						
	(a) Enteric coating of d	iclofenac						
	(b) Co-administration of	-						
	•	ension or <u>l</u> iposomes for			ricin-B			
	(d) Synthesis of an anal			-				
47.	Azithromycin is clinicall		ily as co	mpared to eryth	romycin w	hich is administered		
	every 6 hours because, a	*		_				
	(a) Penetrates into mos		•	•				
		trogen in its lactone ring				t than Erythromycin		
		biotic but not tolerated		ne gastrointestin	al tract			
		l in a sustained release o						
48.	A patient showing musck			nd postural instal	oility was a	dministered levodopa		
	Which of the properties	-						
	(a) Levo-dopa is prefer					rrier		
	(b) Levo-dopa is the lev	orotatory stereoisomer	of 3, 4-d	ihydroxy phenyl	alanine			

(d) Levo-dopa is administered because of its strong antagonistic action on dopamine receptors

(c) Levo-dopa gets decarboxylated in the brain to dopamine

49.				l against a specific pat	hoge	n		
50.	<ul><li>(a) It provided a basis f</li><li>(b) It indicated that spe</li><li>(c) It has not been of m</li></ul>	cific vaccines cannot be des			infec	ted with Heptatitis-B		
51.		es not have phenylethyl am		-				
	(a) Amphetamine	(b) Glyburide	(c)	Pheniramine	(d)	Mescaline		
	Q. 52-58 are multiple selection items. P, Q, R, S are the options. Two of these options are correct. Choose the correct combination from among the alternatives A, B, C and D.							
52.	There are two methods  (P) Binding with resins  (Q) Esterification of am  (R) Forming of complex  (S) Modification of part	of insulin with protein	tion	if insulin may prolong	ed			
53.	(R) Stable in alkaline so		form neutr pH			P, R P, R		
54.	Compared to benzyl pe (P) The amino group re (Q) The spectrum of act (R) The amino group re (S) The phenolic group	enders penicillinase resistar renderspenicillinase resist	ne fol nt to nce to ance	lowing advantages in bacid catalysed degradate the compound to the compound	tion			
55.	<ul><li>(a) P, Q</li><li>The identification of pro</li><li>(P) Gas-chromatograph</li><li>(R) Pycnometer</li><li>(a) P, Q</li></ul>	(b) P, R pellants in pharmaceutical by (b) P, S	aeros (Q) (S)	Tag-open cup appara	atus er	Q, R R, S		

56.	(P) (Q)	edule 'H' and Schedule Prescription drugs wi Standard for cosmetic Biological and special	hich cs	are required to be so					
		List of coal tar colour	-		cosm	etics and soaps			
		P, Q	-	P, R		Q, S	(d)	R, S	
57.		ristica fragrans Houtt. I				*		·	
	(P)	An indeciduous tree,	whicl	h produces drupaceou	ıs, pa	ale yellow fruits			
	(Q)	Each fruit has several aril-the mace, is prese			surf	ace and lignaceous te	gume	ent, and the red fleshy	
	(R)	A deciduous tall tree,			s cap	sules			
	(S)	Each fruit has a unquaril-the mace	e ovo	oid seed, with lignified	d tegi	ument, surrounded by	oran	ge red laciniate fleshy	
	(a)	Q, R	(b)	P, R	(c)	P, S	(d)	Q, S	
58.	In s	ize exclusion chromat	ograj	phy the stationary ph	ases	used are			
	(P)	Alumina	(Q)	Dextran	(R)	Agarose	(S)	Styrene	
	(a)	P, S	(b)	Q, R	(c)	Q, S	(d)	P, R	
amo	ong t	are "Matching" exer the alternatives A,B,C			ur ur	oup II. Choose the C	orrec	e combination from	
59.	Gro	oup I			Gro	oup II			
	Synthetic Drug			Intermediates from which Group I drugs are					
	455					thesized			
	` '	Buclizin				1. Aziridin and thiophosphoryl chloride			
		Chlorphenesin			2.	4-Chlorophenol			
		Thiotepa			3.	4-Chlorobenzhydryl chloride			
		Alprazolam			4.	2-Amino-5-chloro benzophenone			
		P-3, Q-2, R-1, S-4 P-2, Q-4, R-3, S-1				P-4, Q-2, R-1, S-3			
60.	. ,	oup I			. ,	P-1, Q-2, R-4, S-3			
00.		diac Agents			Group II  Mechanism of Action				
		Digitoxin			1.		notro	pic effect by blocking	
	(-)	0				calcium Channels		,	
	(Q)	Dobutamine			2.	Depresses adrener	gicall	y enhanced calcium	
						influx through beta	recep	tor blockade	
	(R)	Sotalol			3.	Causes elevation of	cAMP	levels by stimulation	
						of adenylate Cyclase			
	(S)	Nicardipine			4.	Inhibits membrane ATPase pump	boun	d sodium potassium	

- (a) P-4, Q-3, R-2, S-1
- (c) P-4, Q-2, R-3, S-1

#### 61. Group I

#### Technique employed

- (P) Visible spectrophotometry
- (Q) IR spectrophotometry
- (R) NMR spectrophotometry
- (S) Fluorescence spectrophotometry
- (a) P-2, Q-4, R-3, S-1
- (c) P-3, Q-4,R-1, S-2

#### 62. Group I

#### Amino acids

- (P) Aspartic acid
- (Q) Arginine
- (R) Serine
- (S) Methionine
- (a) P-3, Q-2, R-4, S-1
- (c) P-1, Q-2, R-3, S-4

#### 63. Group I

#### **Tablet defects**

- (P) Picking
- (Q) Sticking
- (R) Mottling
- (S) Lamination
- (a) P-1, Q-2, R-3, S-4
- (c) P-2, Q-4, R-3, S-1

#### 64. Group I

#### Lanatosides

- (P) Lanatoside A
- (Q) Lanatoside B
- (R) Lanatoside C
- (S) Lanatoside D

- (b) P-3, Q-4, R-1, S-2
- (d) P-4, Q-3, R-1, S-2

#### **Group II**

#### Source of Radiation

- 1. R, Source transmitter
- 2. Xenon lamp
- 3. Tungsten lamp
- 4. Nernst glower
- (b) P-3, Q-2, R-1, S-4
- (d) P-4, Q-1, R-3, S-2

#### Group II

# Common degradative products that are citric acid cycle intermediates or their precursors

- 1. Succinyl CoA
- 2. Alpha-Ketoglutarate
- 3. Fumarate
- 4. Pyruvate
- (b) P-3, Q-1, R-4, S-2
- (d) P-4, Q-2, R-3, S-1

#### Group II

#### Explanation

- 1. A term used to describe the surface material from a tab that is sticking to and being removed from the tablet's surface by a punch
- Term refers to tablet material adhering to the die wall
- Term refers to an unequal distribution of colour on a tablet
- Term refers to separation of a tablet into two or more distinct layers
- (b) P-1, Q-3, R-4, S-2
- (d) P-3, Q-1, R-2, S-4

#### **Group II**

#### Aglycone

- 1. Gitoxigenin
- 2. Diginatigenin
- Digoxigenin
- 4. Digitoxigenin

(c) P-3, Q-4, R-2, S-1 (d) P-2, Q-3, R-1, S-4 65. Group I Group II Specific chemical test **Phytoconstituents** (P) Thalleioquin Test Hyoscyamine (Q) Murexide test Barbaloin (R) Vitali-Morin test 3. Quinine (S) Modified Borntrager's test Theobromine (a) P-2, Q-3, R-4, S-1 (b) P-3, Q-4, R-1, S-2 (c) P-1, Q-2, R-3, S-4 (d) P-4, Q-1, R-2, S-3 Data for Q. 66-90 are based on the statement/problem. Choose the correct answer for each question from the option A,B,C,D. Data for (Q.66 - 68) In a formation development laboratory a tablet is to be formulated. The core tablet has a bad taste and requires physical and chemical protection of the drug from moisture. The tablet should also deliver the drug for the local action in the intestine. 66. Suggest a suitable method (a) Sugar coating (b) Film coating (c) Enteric coating (d) Sub coating 67. Choose the correct coating material to be used (a) Sugar (b) Acacia (c) Ethyl cellulose (d) Cellulose acetate phthalate 68. Choose the correct solvent for the coating material (a) Acetone (b) Water (c) Propylene glycol (d) Glycerin Data for (Q.69-70) Compound A with formula  $C_nH_nN$  shows the following important bands in the IR spectra (a) 3423cm<sup>-1</sup>, (b) 3236cm<sup>-1</sup> 69. Assign these bands to the important group in the compound A (c) -CN (d) = C = N(a) -CH, (b) -NH<sub>2</sub> 70. On treatment with nitrous acid the compound A is converted to B, which shows a strong band at 3430cm<sup>-1</sup>. Assign the absorption band for the group formed in the product (b) =C=N-(a) -OH (c) -COOH (d) -N=N-Data for (Q.71-73) In the assay of sulfamethoxazole I.P ( $C_{10}H_{11}N_3O_3S$ ), 0.2g of the sample was dissolved in 50ml of 2M HCl. To this was added 3g of KBr and the titration was carried out. 71. Titration was carried out using (a) NaNO, to estimate the amino group

(b) NaNO, to estimate the sulphonamido group

(d) NaOH to estimate the sulphonamido group

(b) P-1, Q-2, R-4, S-3

(a) P-1, Q-4, R-3, S-2

(c) NaOH to estimate the amino group

72.	The end point in the ass	ay-was determined by							
	(a) Conductometric me	thod	(b)	(b) Using an indicator					
	(c) Potentiometric meth	nod	(d)	Photometric method	l				
73.	If the volume of 0.1 M tit	rant consumed was 7.8 r	nl caku	ate the% purity of th	e san	iple			
	(a) 99.70%	(b) 9.97%	(c)	8.87%	(d)	98.79%			
		Data for	(Q.74-	75)					
A dı	rug which is unstable to l	ight, susceptible to oxyg	en and	gets degraded in pre	sence	of metailic ions, has			
to b	e formulated in the forn	n of a solution for inject	ion.						
74.	Choose a suitable additiv	e to improve the stability	of the i	injection					
	(a) Preservative	(b) Chelating agent	(c)	Buffer	(d)	Tonicity contributor			
75.	Select the appropriate fi	lling and method for the	above p	product					
	(a) Filling in an amber colored ampoule with an addition of antioxidant, replacing the inside air with								
	nitrogen and sealing http://www.xamstudy.com								
	(b) Filling with an antic	xidant dissolved in the s	olution	and sealing the ampo	ule				
	(c) Filling in an amber	(c) Filling in an amber colored ampoule with a preservative and sealing							
	(d) Filling in an ampoul	(d) Filling in an ampoule, sealing and giving direction to store it in dark							
		Data for	(Q.76-	77)					
The	usual adulterants for bu	ds are clove stalks and d	anthopi	hyll					
76.	Clove stalks can be ident	ified by the presence of							
	(a) Starch grains		(b)	Cystoliths					
	(c) Lignified sclereids		(d)	Acicular crystals of c	akiun	n oxalate			
77.	Anthophylli can be ident	ified by the presence of							
	(a) Lignified sclereids		(b)	Acicular crystals of c	akiun	n oxalate			
	(c) Cystoliths		(d) Starch grains						
		Data (Q	). 78-8	0)					
Plai	nt tissue culture of carro	t is being developed in t	he labo	ratory on a semisol	id Wh	ite's medium.			
78.	The micronutrient essen	tial in the medium is							
	(a) NaCl	(b) CoCl <sub>2</sub>	(c)	KCl	(d)	$CaCl_2$			
79.	The pH of the medium is	5							
	(a) 6.6	(b) 6.0	(c)	5.6	(d)	5.0			
80.	The tissue growth obser	ved is							
	(a) Undifferentiated cel	ls suspended in the medi	um						
	(b) Undifferentiated cel	<b>ls</b> in clusters distributed i	in the m	edium					
	(c) Differentiated mass	of cells							
	(d) Surface growth of u	ndifferentiated mass of o	cells						

# Data for (Q. 81-82)

#### In glucose metabolism, name the enzymes catalyzing the following step.

81.	Conversion of glucose to clucose-6-phosphate	e
	(a) Hexokinase	(b) Glucose-6-phosphate dehydrogenase
	(c) Glycogen phosphorylase	(d) Glycogen synthase
82.	Conversion of 2-phosphoglycerate to phosph	noenol pyruvate
	(a) Pyruvate kinase	(b) Phosphoglycerate mytase
	(c) Phosphoglycerate kinase	(d) Enolase
	Data f	for (Q. 83-84)
	hotrexate, trimethoprim and pyrimethamine they are classified in different therapeutic ca	e are all known to be inhibitors of dihydrofolate reductase. Itegories
83.	Trimethoprim has an advantage over methoti	rexate in its therapeutic category because
	(a) Trimethoprim binds to bacterial DHFR a DHFR	about 50,000 times more strongly as compared to the host
	(b) Trimethoprim can be administered orally	<i>'</i>
	(c) Trimethoprim exhibits to significant adve	erse effects
	(d) Trimethoprim has additional anti-inflamm	natory properties
84.	Methotrexate is thought to exert its actions by	y
	(a) Interfering with purine synthesis	(b) Intracellular formation of an amine adduct
	(c) Forming a conjugate with nucleic acids	(d) Inhibiting the synthesis of folic acid
	Data f	for (Q. 85-87)
	idministrative officer having high blood press lapril and tolbutamide.	sure, gastric acidity and diabetes is prescribed famotidine
85.	From the structural features of the drugs, pre-	dict which will be ionized in the stomach
	(a) Famotidine	(b) Enalapril
	(c) Tolbutamide	(d) Enalapril and tolbutamide
86.	The patient cannot tolerate enalapril. Which o	of the following can be substituted?
	(a) Omeprazole	(b) Losartan
	(c) Rosiglitazone	(d) Clofibrate
87.	Famotidine acts as	
	(a) H <sub>1</sub> -histamine antagonist	(b) H <sub>2</sub> -histamine antagonist
	(c) Proton pump inhibitor	(d) H <sub>1</sub> agonist
	Data f	for (Q. 88-90)

2-Methoxy naphthalene on treatment with acetyl chloride in presence of  $AICI_3$  gives 2-acetyl-6-methoxy naphthalene. This is converted with a set of reagents-X to 6-methoxy-2-naphthyl acetic acid, which is esterified with methanol to the mehyl ester. Ester on treatment with Y gives DL-2-(6-methoxy-2-naphthyl)-propionic acid methyl ester. This on hydrolysis gives  $Z(final\ compound)$ 

#### 88. The set of reagents- X are

- (a) Morpholine /Sulphur followed by  $H_2SO_4/H_2O$
- (c) Formic acid/Cu followed by acetic acid
- (b) Morphine/Sulphur followed by HCl/H2O
- (d) Hydroiodic acid followed by  $H_2SO_4/H_2O$

#### 89. Identify the reagents -Y

- (a) NaOH/CH<sub>3</sub>OH
- (c) Hydrazine/CH<sub>3</sub>I

- (b) NaH/CH<sub>3</sub>I
- (d) LiAlH<sub>4</sub>/CH<sub>3</sub>OH

#### 90. The final compound Z is

- (a) Naphazoline
- (b) Carprofen
- (c) Pranoprofen
- (d) Naproxen

# End of paper

# **ANSWER KEY GATE 2004**

1 – a	2 – c	3 – d	4 – c	5 – b	6 – d
7 – b	8 – c	9 – b	10 - c	11 – b	12 – c
13 <b>-</b> b	14 <b>-</b> b	15 – с	16 <b>-</b> a	17 <b>-</b> b	18 <b>-</b> a
19 - a	20 – c	21 – c	22 – a	23 – d	24 – a
25 – c	26 – a	27 – c	28 – d	29 – b	30 - c
31 - b	32 – a	33 – d	34 - b	35 – d	36 <b>-</b> b
37 - c	38 – b	39 – b	40 – a	41 – b	42 – a
43 – b	44 – b	45 <b>-</b> a	46 – c	47 – a	48 <b>-</b> d
49 – b	50 – a	51 – b	52 – a	53 – c	54 – a
55 – b	56 – a	57 – b	58 – b	59 – a	60 – a
61 – c	62 – a	63 – a	64 – c	65 – b	66 – c
67 – d	68 – c	69 – b	70 – a	71 – a	72 – c
73 – a	74 – b	75 – a	76 – c	77 – d	78 – b
79 - с	80 – b	81 <b>-</b> a	82 – d	83 – a	84 - d
85 – a	86 – b	87 – b	88 – a	89 – b	90 – d